Pfizer grows 2% as strategic review continues

2 August 2018 - Deborah Wilkes

Premium

Worldwide sales at Pfizer's Consumer Healthcare business increased by 2% on an operational basis to USD886 million in the second quarter of 2018. Pfizer continues to evaluate strategic alternatives for its Consumer Healthcare business including spin-offs and joint ventures.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: